Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Cash from Operations came in at 30122000.0 in Q4 2025, up 31.1% year-on-year from 22975921.0 in Q4 2024, and up 10.94% on a QoQ basis from 33824000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Cash from Operations (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Cash from Operations data on file, last reported at 30122000.0 in Q4 2025.
- On a quarterly basis, Cash from Operations rose 31.1% year-over-year to 30122000.0 in Q4 2025; TTM through Dec 2025 was 129794000.0, a 33.24% increase from a year earlier, with the FY2025 full-year figure at 129794000.0, up 33.24% from the prior year.
- Cash from Operations for Q4 2025 stood at 30122000.0, up from 33824000.0 in the prior quarter.
- Over the last five years, Cash from Operations for INBX reached as high as 29953000.0 in Q2 2025 and fell as low as 63050000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 43526900.0 across 3 years, with a median of 39807500.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 47.78% in 2025 and fell as far as 11.7% in 2025.
- Year by year, Cash from Operations stood at 56821000.0 in 2023, then advanced by 23.06% to 43720000.0 in 2024, then surged by 31.1% to 30122000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Operations figures were 30122000.0 in Q4 2025, 33824000.0 in Q3 2025, and 29953000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -30.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.12 Mn |
| Dec 31, 2025 | -30.12 Mn |
| Sep 30, 2025 | -33.82 Mn |
| Sep 30, 2025 | -33.82 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Mar 31, 2025 | -35.90 Mn |
| Dec 31, 2024 | -43.72 Mn |
| Dec 31, 2024 | -43.72 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Jun 30, 2024 | -57.36 Mn |
| Jun 30, 2024 | -57.36 Mn |
| Mar 31, 2024 | -63.05 Mn |
| Mar 31, 2024 | -63.05 Mn |
| Dec 31, 2023 | -56.82 Mn |
| Dec 31, 2023 | -56.82 Mn |
| Sep 30, 2023 | -54.25 Mn |
| Sep 30, 2023 | -54.25 Mn |